625 related articles for article (PubMed ID: 27853906)
1. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA
Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906
[TBL] [Abstract][Full Text] [Related]
2. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
3. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
4. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
5. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
6. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
7. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.
Hamel KM; King CT; Cavalier MB; Liimatta KQ; Rozanski GL; King TA; Lam M; Bingham GC; Byrne CE; Xing D; Collins-Burow BM; Burow ME; Belgodere JA; Bratton MR; Bunnell BA; Martin EC
Stem Cells Dev; 2022 Oct; 31(19-20):604-620. PubMed ID: 35579936
[TBL] [Abstract][Full Text] [Related]
9. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
11. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
[TBL] [Abstract][Full Text] [Related]
12. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
15. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia reduces hormone responsiveness of human breast cancer cells.
Kurebayashi J; Otsuki T; Moriya T; Sonoo H
Jpn J Cancer Res; 2001 Oct; 92(10):1093-101. PubMed ID: 11676860
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
[TBL] [Abstract][Full Text] [Related]
18. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype.
Shah SH; Miller P; Garcia-Contreras M; Ao Z; Machlin L; Issa E; El-Ashry D
Cancer Biol Ther; 2015; 16(11):1671-81. PubMed ID: 26186233
[TBL] [Abstract][Full Text] [Related]
19. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
Chen X; Danes C; Lowe M; Herliczek TW; Keyomarsi K
J Natl Cancer Inst; 2000 Sep; 92(17):1403-13. PubMed ID: 10974076
[TBL] [Abstract][Full Text] [Related]
20. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
Hall JM; Korach KS
Mol Endocrinol; 2003 May; 17(5):792-803. PubMed ID: 12586845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]